Drugs / GSK2793660
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02058407 | Jan → Oct 2014 | bronchiectasis | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2793660 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02058407 ↗ |
| Action | Inhibit | “GSK2793660 is an oral, irreversible inhibitor of CTSC that is hypothesized to provide an alternative route to achieve NE inhibition and was tested in a Phase I study.” PMID 28800383 ↗ Sep 2017 |
| Route | Oral | “GSK2793660 is an oral, irreversible inhibitor of CTSC that is hypothesized to provide an alternative route to achieve NE inhibition and was tested in a Phase I study.” PMID 28800383 ↗ Sep 2017 |
| Target | CTSC | “GSK2793660 is an oral, irreversible inhibitor of CTSC that is hypothesized to provide an alternative route to achieve NE inhibition and was tested in a Phase I study.” PMID 28800383 ↗ Sep 2017 |